Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial

Diabetologia

Volumn 59, Issue 3, 2016, Pages 453-461

  Kuwata, Hitoshi ^a   Iwasaki, Masahiro ^a,b   Shimizu, Shinobu ^a   Minami, Kohtaro ^b   Maeda, Haruyo ^b   Seino, Susumu ^b   Nakada, Koji ^c   Nosaka, Chihiro ^d   Murotani, Kenta ^e   Kurose, Takeshi ^a   Seino, Yutaka ^a   Yabe, Daisuke ^a,b  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KYOWA HAKKO KOGYO CO LTD   (Japan)

^e AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Gastric emptying; GIP; GLP 1; Meal sequence; Postprandial glucose variability

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET THERAPY; EXPLORATORY RESEARCH; FEMALE; FISH MEAL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; MALE; MEAT; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RICE; STOMACH EMPTYING; BLOOD; DIET; JAPAN; MEAL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS);

ADULT; AGED; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIET; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INCRETINS; INSULIN; JAPAN; MALE; MEALS; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 84957440012     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3841-z     Document Type: Article

References (41)

1. Smith-Palmer J, Brandle M, Trevisan R, Orsini Federici M, Liabat S, Valentine W (2014) Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract 105:273–284
2. The DECODE study group on behalf of the European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617–621
3. Leiter LA, Ceriello A, Davidson JA et al (2005) Postprandial glucose regulation: new data and new implications. Clin Ther 27(Suppl B):S42–S56
4. Evert AB, Boucher JL, Cypress M et al (2014) Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 37(Suppl 1):S120–S143
5. Imai S, Matsuda M, Hasegawa G et al (2011) A simple meal plan of ‘eating vegetables before carbohydrate’ was more effective for achieving glycemic control than an exchange-based meal plan in Japanese patients with type 2 diabetes. Asia Pac J Clin Nutr 20:161–168
6. Ma J, Stevens JE, Cukier K et al (2009) Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 32:1600–1602
7. Gentilcore D, Chaikomin R, Jones KL et al (2006) Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab 91:2062–2067
8. Phillips LK, Deane AM, Jones KL, Rayner CK, Horowitz M (2014) Gastric emptying and glycaemia in health and diabetes mellitus. Nat Rev Endocrinol 11:112–128
9. Phillips LK, Rayner CK, Jones KL, Horowitz M (2014) Measurement of gastric emptying in diabetes. J Diabet Complicat 28:894–903
10. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409–1439
11. Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 1:9–23
12. Drucker DJ (2013) Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62:3316–3323
13. Seino Y, Yabe D (2013) Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 4:108–130
14. Yabe D, Seino Y (2014) Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes. Expert Rev Endocrinol Metab 9:659–670
15. Samocha-Bonet D, Wong O, Synnott EL et al (2011) Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. J Nutr 141:1233–1238
16. Hirasawa A, Tsumaya K, Awaji T et al (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90–94
17. Morishita M, Tanaka T, Shida T, Takayama K (2008) Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J Control Release 132:99–104
18. Seino Y, Nanjo K, Tajima N et al (2010) Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 1:212–228
19. Tajima N, Noda M, Origasa H et al (2015) Evidence-based practice guideline for the treatment for diabetes in Japan 2013. Diabetol Int 6:151–187
20. Yabe D, Watanabe K, Sugawara K et al (2012) Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Investig 3:70–79
21. Sanaka M, Nakada K (2010) Stable isotope breath tests for assessing gastric emptying: a comprehensive review. J Smooth Muscle Res 46:267–280
22. Yabe D, Rokutan M, Miura Y et al (2013) Enhanced glucagon-like peptide-1 secretion in a patient with glucagonoma: implications for glucagon-like peptide-1 secretion from pancreatic alpha cells in vivo. Diabetes Res Clin Pract 102:e1–4
23. Sanaka M, Nakada K, Nosaka C, Kuyama Y (2007) The Wagner-Nelson method makes the [13C]-breath test comparable to radioscintigraphy in measuring gastric emptying of a solid/liquid mixed meal in humans. Clin Exp Pharmacol Physiol 34:641–644
24. Shin AS, Camilleri M (2013) Diagnostic assessment of diabetic gastroparesis. Diabetes 62:2667–2673
25. Ma J, Checklin HL, Wishart JM et al (2013) A randomised trial of enteric-coated nutrient pellets to stimulate gastrointestinal peptide release and lower glycaemia in type 2 diabetes. Diabetologia 56:1236–1242
26. Wu T, Bound MJ, Standfield SD, Jones KL, Horowitz M, Rayner CK (2013) Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab 98:E718–E722
27. Wolever TM, Bentum-Williams A, Jenkins DJ (1995) Physiological modulation of plasma free fatty acid concentrations by diet. Metabolic implications in nondiabetic subjects. Diabetes Care 18:962–970
28. Jovanovic A, Gerrard J, Taylor R (2009) The second-meal phenomenon in type 2 diabetes. Diabetes Care 32:1199–1201
29. Chen MJ, Jovanovic A, Taylor R (2010) Utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack. Diabetes Care 33:2552–2554
30. Jakubowicz D, Froy O, Ahren B et al (2014) Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial. Diabetologia 57:1807–1811
31. Itoh K, Moriguchi R, Yamada Y et al (2014) High saturated fatty acid intake induces insulin secretion by elevating gastric inhibitory polypeptide levels in healthy individuals. Nutr Res 34:653–660
32. Lardinois CK, Starich GH, Mazzaferri EL (1988) The postprandial response of gastric inhibitory polypeptide to various dietary fats in man. J Am Coll Nutr 7:241–247
33. Iwasaki M, Hoshian F, Tsuji T et al (2012) Predicting efficacy of DPP-4 inhibitors in patients with type 2 diabetes: association of HbA1c reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Investig 3:464–467
34. Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728–742
35. Kawamori D, Welters HJ, Kulkarni RN (2010) Molecular pathways underlying the pathogenesis of pancreatic alpha-cell dysfunction. Adv Exp Med Biol 654:421–445
36. Holst JJ, Christensen M, Lund A et al (2011) Regulation of glucagon secretion by incretins. Diabetes Obes Metab 13(Suppl 1):S89–S94
37. Lund A, Bagger JI, Christensen M, Knop FK, Vilsboll T (2014) Glucagon and type 2 diabetes: the return of the alpha cell. Curr Diab Rep 14:555
38. Yabe D, Kuroe A, Watanabe K et al (2015) Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. J Diab Complicat 29:413–421
39. Yabe D, Seino Y, Fukushima M, Seino S (2015) Beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep 15:602
40. Calanna S, Christensen M, Holst JJ et al (2013) Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 56:965–972
41. Ezcurra M, Reimann F, Gribble FM, Emery E (2013) Molecular mechanisms of incretin hormone secretion. Curr Opin Pharmacol 13:922–927